Barbosa Pedro, Lees Andrew J, Magee Cathy, Djamshidian Atbin, Warner Thomas T
Reta Lila Weston Institute of Neurological Studies Institute of Neurology University College London London United Kingdom.
The National Hospital for Neurology and Neurosurgery London United Kingdom.
Mov Disord Clin Pract. 2016 Aug 11;4(3):323-328. doi: 10.1002/mdc3.12416. eCollection 2017 May-Jun.
Impulsive compulsive behaviors (ICBs) can have a deleterious impact on the lives of patients with PD with orally active dopamine agonist treatment recognized as the greatest risk factor. However, the relationship between subcutaneous administration of the dopamine agonist, apomorphine, and impulsive compulsive behaviors is unknown.
We conducted a retrospective analysis of 28 advanced PD patients treated with subcutaneous waking day apomorphine ambulatory minipumps at the National Hospital for Neurology and Neurosurgery (London, UK).
Twelve of the patients had experienced impulsive compulsive behaviors before starting apomorphine. Reduction of oral dopamine agonist dose before apomorphine had led to complete resolution in 6 cases with no recurrence on long-term apomorphine maintenance therapy. Six patients still had active impulsive compulsive behaviors when apomorphine was started. Four of these improved, and in the other 2 there was no worsening. Of the 16 patients with no previous history of impulsive compulsive behaviors who started apomorphine, only 1, who was still receiving concurrent levodopa, developed impulsive compulsive behaviors.
These data provide preliminary evidence that continuous apomorphine pump therapy has a lower proclivity to trigger or exacerbate impulsive compulsive behaviors than oral dopamine agonists. This is likely to be attributed to a more tonic stimulation of striatal dopamine receptors leading to desensitisation, but could also be attributed to a different pharmacological profile of apomorphine compared with orally active dopamine agonists. Apomorphine can be considered as a treatment option in patients who have developed disabling impulsive compulsive behaviors on oral agonist therapy whose motor handicap cannot be controlled adequately on l-dopa alone. Further prospective studies are needed to provide a definitive answer to this question.
冲动强迫行为(ICBs)会对帕金森病(PD)患者的生活产生有害影响,口服活性多巴胺激动剂治疗被认为是最大的风险因素。然而,多巴胺激动剂阿扑吗啡皮下给药与冲动强迫行为之间的关系尚不清楚。
我们对英国伦敦国家神经病学和神经外科医院28例接受皮下清醒日阿扑吗啡门诊微型泵治疗的晚期PD患者进行了回顾性分析。
12例患者在开始使用阿扑吗啡之前曾经历过冲动强迫行为。在使用阿扑吗啡之前减少口服多巴胺激动剂剂量,导致6例患者症状完全缓解,长期阿扑吗啡维持治疗未复发。6例患者开始使用阿扑吗啡时仍有活跃的冲动强迫行为。其中4例有所改善,另外2例未加重。在开始使用阿扑吗啡且既往无冲动强迫行为史的16例患者中,只有1例仍在同时接受左旋多巴治疗的患者出现了冲动强迫行为。
这些数据提供了初步证据,表明持续阿扑吗啡泵治疗比口服多巴胺激动剂引发或加重冲动强迫行为的倾向更低。这可能归因于对纹状体多巴胺受体的更持续刺激导致脱敏,但也可能归因于与口服活性多巴胺激动剂相比,阿扑吗啡具有不同的药理学特征。对于在口服激动剂治疗时出现致残性冲动强迫行为且仅用左旋多巴无法充分控制运动障碍的患者,可考虑将阿扑吗啡作为一种治疗选择。需要进一步的前瞻性研究来明确回答这个问题。